Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.
Betacoronavirus
/ immunology
COVID-19
Comorbidity
Coronavirus Infections
/ diagnosis
Diphosphonates
/ therapeutic use
Disease Management
Expert Testimony
Glucocorticoids
/ adverse effects
Histamine Antagonists
/ therapeutic use
Humans
Immunosuppressive Agents
/ adverse effects
Mast Cells
/ drug effects
Mastocytosis, Cutaneous
/ diagnosis
Mastocytosis, Systemic
/ diagnosis
Myeloablative Agonists
/ adverse effects
Pandemics
Pneumonia, Viral
/ diagnosis
Precision Medicine
/ methods
Risk Factors
SARS-CoV-2
Vitamin D
/ therapeutic use
COVID-19
KIT D816V
Mast cells
SARS-CoV-2
coronavirus
mast cell activation syndrome
mastocytosis
tryptase
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
13
05
2020
revised:
05
06
2020
accepted:
10
06
2020
pubmed:
21
6
2020
medline:
26
8
2020
entrez:
21
6
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.
Identifiants
pubmed: 32561389
pii: S0091-6749(20)30839-3
doi: 10.1016/j.jaci.2020.06.009
pmc: PMC7297685
pii:
doi:
Substances chimiques
Diphosphonates
0
Glucocorticoids
0
Histamine Antagonists
0
Immunosuppressive Agents
0
Myeloablative Agonists
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
300-306Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Allergy Clin Immunol. 2010 Dec;126(6):1099-104.e4
pubmed: 21035176
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Allergy Clin Immunol. 2014 May;133(5):1471-4
pubmed: 24472624
Eur J Haematol. 2015 Jun;94(6):474-90
pubmed: 25753531
Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):421-34
pubmed: 17880756
Ir Med J. 2020 Apr 03;113(4):58
pubmed: 32268051
Allergy. 2018 Jan;73(1):230-238
pubmed: 28662309
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Curr Opin Immunol. 2007 Feb;19(1):31-8
pubmed: 17126541
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
J Clin Oncol. 2014 Oct 10;32(29):3264-74
pubmed: 25154823
Leukemia. 2015 Jun;29(6):1223-32
pubmed: 25650093
Leuk Res. 2001 Jul;25(7):603-25
pubmed: 11377686
Blood. 2010 Dec 23;116(26):5812-7
pubmed: 20855864
JAMA. 2020 Feb 25;323(8):709-710
pubmed: 31999307
Leuk Res. 2020 Mar 26;92:106353
pubmed: 32251934
J Biol Regul Homeost Agents. 2019 Feb 4;34(1):9-14
pubmed: 32013309
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nutrition. 2020 Jun;74:110835
pubmed: 32280058
N Engl J Med. 2015 Jul 9;373(2):163-72
pubmed: 26154789
Clin Exp Allergy. 2020 Jun;50(6):654-661
pubmed: 32107810
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1125-1133.e1
pubmed: 30737190
J Allergy Clin Immunol. 2016 Jan;137(1):35-45
pubmed: 26476479
Int Arch Allergy Immunol. 2012;157(3):215-25
pubmed: 22041891
Eur J Immunol. 2010 Jul;40(7):1843-51
pubmed: 20583030
Blood. 2007 Jun 15;109(12):5293-300
pubmed: 17351109
Eur J Clin Invest. 2007 Jun;37(6):435-53
pubmed: 17537151
Nature. 1996 May 2;381(6577):77-80
pubmed: 8609993
Allergy. 2013 Apr;68(4):417-24
pubmed: 23409940
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
J Clin Immunol. 2018 May;38(4):457-459
pubmed: 29748908
J Allergy Clin Immunol. 2004 Jul;114(1):3-11; quiz 12
pubmed: 15241337
Blood. 2003 Dec 15;102(13):4270-6
pubmed: 12933573
Int J Mol Sci. 2019 Jun 18;20(12):
pubmed: 31216696
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589
pubmed: 32297519
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
N Engl J Med. 2016 Jun 30;374(26):2530-41
pubmed: 27355533
Ann Palliat Med. 2020 Mar;9(2):428-436
pubmed: 32233642
J Immunol. 2010 Jun 15;184(12):7108-15
pubmed: 20483738
Blood. 2017 Mar 16;129(11):1420-1427
pubmed: 28031180
Blood. 2008 Aug 15;112(4):946-56
pubmed: 18684881
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Blood. 2020 Apr 16;135(16):1365-1376
pubmed: 32106312
Nat Genet. 2016 Dec;48(12):1564-1569
pubmed: 27749843
Obesity (Silver Spring). 2020 Jul;28(7):1176-1177
pubmed: 32299148
Ann Oncol. 2017 Oct 1;28(10):2367-2376
pubmed: 28945834
Nutrients. 2020 Apr 02;12(4):
pubmed: 32252338
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9190-5
pubmed: 21576486
Clin Exp Allergy. 2017 Mar;47(3):351-360
pubmed: 28008678